SATB2 and neoplasm: Thus, inhibiting the transcriptional activity of SATB2/CBP by the CBP inhibitor potently suppresses GBM tumor growth, suggesting that targeting this signaling axis may be a promising therapeutic strategy to effectively improve GBM treatment.